Medicinal chemist, Organic chemist, Drug discovery

1. Curriculum Vitae
Andrew Kleinberg
510 Lakeville Lane
East Meadow, NY 11554
Phone: (516) 965-2174 Email: andrewkleinberg@gmail.com
PROFESSIONAL PROFILE
• Results-oriented synthetic organic chemist with 8 years of research experience in biotech,
developing kinase inhibitors as anti-cancer agents
• Skilled at designing and synthesizing small-molecule inhibitors, tracking SAR and conceiving of
ways to improve the chemical matter
• Consistently received top productivity scores in the chemistry department
• Understands the importance of the balance between potency and physical properties in designing
drug-like compounds, including more cutting-edge statistics like Lipophilic Ligand Efficiency
• Great success working on all scales of reactions, with specialty in small-scale reactions for
generating final compounds with high efficiency
• Very experienced with literature-searching software (SciFinder) for quick optimization of
proprietary reactions
• Highly skilled in use of analytical equipment like LC/MS and NMR
• Proficient with many forms of compound purification, including silica gel chromatography,
triturations, reverse-phase HPLC, SFC and Solid-Phase Extraction cartridges
• Excellent communication skills, both with supervisors and in group presentations
• Acquired managerial experience while training and supervising a chemistry intern for more than a
year
• 5 times received company “SPOT” award, for recognition of above-and-beyond effort in the
chemistry department
• Friendly, team-oriented employee, always willing to spare time to help others
PROFESSIONAL EXPERIENCE
OSI Pharmaceuticals 5/2005 – 5/2013
Associate Scientist 1/2010 – 5/2013
Team member on the TAK1 inhibitor program
• Managed a chemistry intern for 14 months in support of synthetic efforts for project team
• Pioneered chemistry around key benzothiadiazole pharmacophore, leading to advanced potency,
PK and selectivity for series
• Performed majority of in vivo scale-ups for lead compounds, consistently ahead of timelines
• Led synthetic efforts from initial hits to development candidates on furopyridine series
• Designed and pioneered a novel synthetic approach to a key core intermediate by utilizing a
cycloisomerization strategy
• Helped team drive new series from early stages to compounds rivaling previous advanced series
within a few months, using lessons of physical properties and personally designing key
pharmacophores
Senior Research Associate 6/2007 –
12/2009

2. Team member on the MET/RON dual-inhibitor program
• Spear-headed synthetic efforts to two development candidates on furopyridine and azaindole
series
• Performed 100 g rat tox scale-up of development candidate to 99% purity
• Joined High-Speed Analog group, synthesizing 500+ final compounds in small quantities per
person per year
• Credited with design of first development candidate for MET/RON program after major analog
campaign which I personally conceived and performed, including scale-up of lead compound
• Developed 3-step, 1-pot method for another major analog campaign towards potency optimization
(Mitsunobu  nitro-reduction  de-BOC  HPLC purification of final compound, 3 hours
time)
• Screened chiral-auxiliaries on key racemate core intermediate for separation of diasteriomers to
identify and profile the desired enantiomer of final compounds, before chiral SFC was available
• Pioneered metallation chemistry to synthesize key selectivity pharmacophore, used in
development candidate
• Performed majority of in vivo scale-ups for lead compounds and PK-screenings, consistently
ahead of timelines
Team member on the ACK1 inhibitor program
• Explored and developed a microwave assisted, Cu(I)-mediated coupling reaction to enable a
major analog campaign of diaryl-ether pharmacophore, when conventional heating was not
working
• Generated high quality lead compounds with excellent potency, selectivity and bioavailability in a
period of 5 months, using systematic SAR exploration around the lipophilic binding site
Research Associate 8/2005 –
6/2007
Team member on the IGF-1R BU inhibitor program
• Synthesized analogs around key quinoline pharmacophore, leading to serendipitous discovery of
slow off-rate inhibitors
• Performed analog campaign of amides and various bioisosteres, leading to identification of
potential development candidate back-up, which was scaled up for in vivo profiling in tumors
• Began tenure at OSI as a summer intern, and then hired full-time
EDUCATION
M.S., Chemistry, St. John’s University, 2011
Advisor: Professor Victor Cesare
B.S., Chemistry, Penn State University, University Park, 2004
PUBLICATIONS
1. Jin, M.; Wang, J.; Kleinberg, A.; Kadalbajoo, M.; et al. Discovery of potent, selective and orally
bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors. Bioorg. Med.Chem.
Lett. 2013, 23, 979-984
2. Jin, M.; Kleinberg, A.; Cooke, A.; Gokhale, P.; Foreman, K.; Dong, H.; Siu, K.; Bittner, M.;
Mulvihill, K.; Yao, Y.; et al. Potent and selective cyclohexyl-derived imidazopyrazine insulin-like
growth factor 1 receptor inhibitors with in vivo efficacy. Bioorg. Med.Chem.

3. Lett. 2011, 21(4), 1176-1180
3. Jin, M.; Gokhale, P.; Cooke, A.; Foreman, K.; Buck, E.; May, E.; Feng, L.; Bittner, M.; Kadalbajoo,
M.; Landfair, D.; Kleinberg, A.; et al. Discovery of an Orally Efficacious Imidazo[5,1-f]
[1,2,4]triazine Dual Inhibitor of IGF-1R and IR. ACS Med. Chem.
Lett. 2010, 1(9), 510-515
4. Li, A.; Beard, D.; Coate, H.; Honda, A.; Kadalbajoo, M.; Kleinberg, A.; Laufer, R.; Mulvihill, K.;
Nigro, A.; Rastogi, P.; et al. One-pot Friedlander quinoline synthesis: scope and
limitations. Synthesis 2010, (10), 1678-1686
PATENTS
1. Hornberger, K.; Berger, D.; Chen, X.; Crew, A.; Dong, H.; Kleinberg, A.; Li, A.; Ma, L.; Mulvihill,
M.; Panicker, B.; Siu, K.; Steinig, A.; Tarrant, J.; Wang, J.; Weng, Q.; Sangem, R.; Gupta, R.; : 7-
Aminofuropyridine derivatives. Feb. 23 2012:US20120046267
2. Muvilhill, M.; Steinig, A.; Crew, A.; Jin, M.; Kleinberg, A.; Li, A.; Wang, J. : Fused Bicyclic Kinase
Inhibitors. OSI Pharmaceuticals. Nov, 17 2011: US20110281888
3. Li, A.; Steinig, A.; Kleinberg, A.; Weng, Q.; Muvilhill, M.; Wang, J.; Chen, X.; Wang, T.; Dong, H.;
Jin, M. : Furo[3,2-c]pyridines. OSI Pharmaceuticals. Sep. 20 2011: US8022206
4. Chen, X.; Jin, M.; Kleinberg, A.; Li, A.; Muvilhill, M.; Steinig, A.; Wang, J. : Substituted
Pyrrolo[2,3-b]-Pyridines and -Pyrazines. OSI Pharmaceuticals. Sep. 15 2011: US20110224191
5. Crew, A.; Jin, M.; Kadalbajoo, M.; Kleinberg, A.; Muvilhill, M.; Wang, J. : Substituted Imidazopyr-
and Imidazotri-azines. OSI Pharmaceuticals. Nov. 19 2009: US20090286768
6. Li, A.; Steinig, A.; Kleinberg, A.; Qinghua Weng, Muvilhill, M.; Wang, J.; Chen, X.; Wang, T.;
Dong, H.; Jin, M. : Furo- And Thieno [3,2-c] Pyridines. OSI Pharmaceuticals. Aug. 6
2009: US20090197864
HOBBIES AND INTERESTS
• Managed company softball team
• Huge Mets fan
• Active in company charity events (Camp Adventure, Lustgarten Cancer Walk, charity sports
competitions, beard-growing fundraisers)
• Bowling league
References Available Upon Request